P-377 Prognostic stratification of TAS-102 treatment
نویسندگان
چکیده
In metastatic colorectal cancer (mCRC) the choice of treatment should take into account characteristics tumor and patient, as well its efficacy tolerability. The RECOURSE study demonstrated that presence low burden indolent disease has an impact on progression-free (PFS) overall (OS) survival patients treated with trifluridine/tipiracil (TAS-102). Retrospective included mCRC undergoing TAS-102 from January 2017 to December 2021. analysis was performed considering two subgroups: good prognosis (GP) - (1 or 2 metastasis sites time ≥ 18 months since diagnosis initiation TAS-102) poor (PP) (≥ 3 metastasized and/or < initiation). Survival using Kaplan-Meier method log-rank test. prognostic assessed Cox regression model. A total 85 were included, 51.8% (n=44) male, a median age 65 years [24-85]. About 58.8% (n=50) at 61.2% had mutation in RAS gene. 80% (n=68) ECOG performance status 0-1, 45.9% (n=39) 72.9% (n=62) liver metastases. sample, 48.2% (n=41) GP PP. 84.7% (n=72) patients, 3rd 4th line treatment. Median follow-up (1-18). There statistically significant OS PFS taking subgroups (median 5 months, 95%CI 4.1-5.9 versus PP 2.5-3.6, p=0.001; 13 7.4-18.6 4.3-5.7, p 0.001). multivariate analysis, features identified independent factor (HR 0.52, 0.3-0.9, p=0.017) 0.47, 0.3-0.8, p=0.004). Mutated tumors associated worse 1.7, 1.7-2.8, p=0.035). our greater observed GHP mCRC. Taking advanced stage disease, patient's vulnerability socio-economic impact, selection who benefit this therapy becomes increasingly relevant attempt avoid therapeutic obstinacy underlying iatrogenesis.
منابع مشابه
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
BACKGROUND Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS In this double-blind study, we randomly ass...
متن کاملDrug-induced Pneumonitis Following the Administration of TAS-102
A 59-year-old woman, diagnosed with advanced rectal cancer, presented with a low-grade fever and dyspnea on exertion after the 2nd cycle of TAS-102. TAS-102 has promising efficacy in patients with metastatic colorectal cancer. A CT scan revealed mosaic patterns with bilateral ground-glass opacities. The drug lymphocyte stimulation test for TAS-102 was strongly positive and serum β-D glucan leve...
متن کاملDifference in Neutropenia due to Administration Schedule of TAS-102
TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by c...
متن کاملInterstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
BACKGROUND TAS-102, a new treatment option for patients with metastatic colorectal cancer that is refractory or intolerant to standard therapies, has been improving survival with acceptable tolerability and adverse events. Adverse hematological events associated with TAS-102 treatment were extensively profiled in the RECOURSE trial, but pulmonary toxicities associated with TAS-102 therapy are d...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2023
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2023.04.433